Concentration Determination of Tulathromycin Residues (CP-60,300) in Liver and Injection Site Tissues of Goats Receiving One Subcutaneous Injection of DRAXXIN 25 (25 mg/mL) at 2.5 mg/kg Bodyweight

PROJECT SUMMARY This project aims to address the significant problem of bacterial pneumonia in goats, which is a major cause of morbidity and mortality and represents a significant welfare challenge for operations in the United States. Currently, there is only one FDA-approved antibiotic for the treatment of respiratory disease in goats, which requires daily administration. That decreases

efficacy in situations where owner compliance with labeled instructions is lacking. To address this problem, the proposed research aims to determine an appropriate withdrawal period following administration of Draxxin® 25 in goats except breeding and lactating goats. The expected outcome is to have quantified data from incurred liver and injection site tissues that

can be utilized to determine a meat withdrawal period. Following completion of this work, we will have completed all the work associated with all the necessary technical sections which we be able to submit to FDA CVM for consideration for a label approval. The label approval of Draxxin® 25 will make it easier for veterinarians to use tulathromycin in goats with confidence in

scientifically based labeled slaughter withdrawal times.